Abstracts tagged "Dermatology"

Abstract Number: 0093 • ACR Convergence 2024
Overexpression of Epidermal Ifnk Promotes Systemic CD8+ T Cell Maturation After UV-exposure
Benjamin Klein¹, Kelsey E. McNeely², Debbie Colesa², Yiqing Gao², Nguyen Thi Kim Nguyen², Johann Gudjonsson¹ and J. Michelle Kahlenberg¹, ¹University of Michigan, Ann Arbor, MI, ²University of Michigan Michigan Medicine, Ann Arbor, MI
Background/Purpose: Skin involvement is the most common organ manifestation in systemic lupus erythematosus (SLE), and exacerbation of cutaneous lupus (CLE) can precede systemic disease flares.…
Abstract Number: 2153 • ACR Convergence 2024
Construct Validity of the IDEOM Musculoskeletal Questionnaire (IDEOM MSK-Q) Using Data from the Cohort for Psoriasis and Psoriatic Arthritis Registry (COPPAR)
Lourdes Perez Chada¹, Ruogu Li², vivi feathers², Kumiko Schnock², Helen Early², Grace Carter², Neda Shahriari², Arianna Zhang², Jing Cui³, Michael Weinblatt⁴, Nancy Shadick², Alice Gottlieb⁵ and Joseph Merola⁶, ¹Harvard Medical School, Wayland, MA, ²Brigham and Women's Hospital, Boston, MA, ³Brigham Women's Hospital, Boston, MA, ⁴Brigham and Women's Hospital/ Harvard Medical School, Waban, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Patients with psoriasis often present with musculoskeletal (MSK) symptoms, yet validated instruments to measure MSK symptoms in this population are limited. The IDEOM MSK-Q…
Abstract Number: 0328 • ACR Convergence 2024
IFI27 Is Differentially Upregulated in Anti-MDA5 Dermatomyositis and Correlates with the Presence of Interstitial Lung Disease
Melissa Leeolou¹, Lorinda Chung², Kavita Sarin³ and david fiorentino⁴, ¹Stanford University School of Medicine, Redwood City, CA, ²Stanford University, Woodside, CA, ³Department of Dermatology, Stanford University School of Medicine, Redwood City, CA, ⁴Department of Dermatology, Stanford University School of Medicine, Stanford, CA, Palo Alto, CA
Background/Purpose: Type I interferon (IFN) plays a role in the pathogenesis of dermatomyositis (DM) and correlates with measures of disease activity. Melanoma differentiation-associated gene 5…
Abstract Number: 2320 • ACR Convergence 2024
Nailfold Videocapillaroscopy Findings in Patients with Psoriatic Disease: Is There a Distinctive Psoriatic Pattern?
Eduardo Briones-García¹, Tatiana Sofía Rodríguez-Reyna², Eduardo Martin Nares², Guillermo A Guaracha-Basañez³ and Iris Paola García Herrera⁴, ¹Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán. Immunology and Rheumatology Department., Ciudad de México, Distrito Federal, Mexico, ²Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico, ³Instituto Nacional de Ciencias Medicas y Nutricion “Salvador Zubirán”, Mexico City, Distrito Federal, Mexico, ⁴Department of Immunology and Rheumatology, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City, Mexico
Background/Purpose: The utility of nailfold videocapillaroscopy (NVC) in conditions such as systemic sclerosis and primary Raynaud´s phenomenon is well known. Whether patients with psoriatic disease…
Abstract Number: 0594 • ACR Convergence 2024
Real-world Experience of Bimekizumab for Plaque Psoriasis in Adult Patients with Prior Exposure to Interleukin-17 Inhibitors: A 16-week Multicenter Retrospective Review
Siddhartha Sood¹, Alexander Rimke², Brian Rankin³, Abrahim Abduelmula⁴, jorge Georgakopoulos⁴, Khalad Maliyar⁴, Ahmed Bagit⁵, Fernejoy Leung⁶, Alim Devani⁶, Ronald Vender⁷, Jensen Yeung⁴ and Vimal Prajapati³, ¹Temerty Faculty of Medicine, University of Toronto, Toronto, ON, Canada, ²Dermatology Research Institute, Calgary, AB, Canada, ³Division of Dermatology, Department of Medicine, University of Calgary, Calgary, AB, Canada, ⁴Division of Dermatology, Department of Medicine, University of Toronto, Toronto, Canada, ⁵Temerty Faculty of Medicine, University of Toronto, Toronto, Canada, ⁶Skin Health & Wellness Centre, Calgary, AB, Canada, ⁷Division of Dermatology, Department of Medicine, McMaster University, Hamilton, Canada
Background/Purpose: While biologic switching is common in routine clinical practice, limited information exists on switching within class from another IL-17i to bimekizumab. We conducted a…
Abstract Number: 2348 • ACR Convergence 2024
Bimekizumab Efficacy and Safety Through 4 Years in Moderate to Severe Plaque Psoriasis: Long-Term Results from a Phase 3 Study and Open-Label Extension
Diamant Thaçi¹, Luis Puig², Joseph F. Merola³, Denis Jullien⁴, Antonio Costanzo⁵, Maggie Wang⁶, Delphine Deherder⁷, José M. López Pinto⁸ and Mark Lebwohl⁹, ¹Institute and Comprehensive Center for Inflammation Medicine, University of Lübeck, Lübeck, Schleswig-Holstein, Germany, ²Hospital de la Santa Creu i Sant Pau, Universitat Autònoma de Barcelona, Barcelona, Spain, ³UT Southwestern Medical Center, Dallas, TX, ⁴Department of Dermatology, Hôpital Edouard Herriot, Hospices Civils de Lyon, University of Lyon, Lyon, France, ⁵Department of Dermatology, Humanitas Clinical and Research Centre, IRCCS, Rozzano, Milan, Italy, ⁶UCB Pharma, Morrisville, NC, ⁷UCB Pharma, Braine-l'Alleud, Belgium, ⁸UCB Pharma, Madrid, Spain, ⁹Department of Dermatology, Icahn School of Medicine at Mount Sinai, New York, NY
Background/Purpose: Clinical improvements through Week 152, with no unexpected safety findings, were previously reported with bimekizumab (BKZ) in the BE SURE phase 3 trial and…
Abstract Number: 0596 • ACR Convergence 2024
Impact of a Multidisciplinary Rheumatology-Dermatology-Gastroenterology Center in the Management of Patients with Psoriatic Arthritis: Analysis of the First 5-years of Implementation
Marina Sánchez-Lucas¹, Camille Bourgeois¹, Juan Molina-Collada², Teresa Gonzalez-Hernandez¹, Juan Carlos Nieto Gonzalez¹, Amparo Lopez-Esteban¹, Ofelia Baniandres¹, Esther Chamorro de Vega¹ and Isabel Castrejon³, ¹Hospital Universitario Gregorio Marañón, Madrid, Spain, ²Hospital General Universitario Gregorio Marañón, Madrid, Spain, ³Hospital General Universitario Gregorio Marañon, Madrid, Spain
Background/Purpose: Psoriatic arthritis (PsA) has a heterogenous clinical phenotype with manifestations in a number of different organs and systems. These include not only enthesitis, synovitis…
Abstract Number: 2640 • ACR Convergence 2024
Comparative Safety and Use of Non-conventional Combination Targeted Therapy in Adults with Psoriatic Arthritis
Alexander Wu¹, Arianna Zhang², Yujia Guo¹, Jialing Liu¹, Donghan Yang¹, Lourdes Perez Chada³, Alexis Ogdie⁴, Jose Scher⁵ and Joseph Merola⁶, ¹University of Texas Southwestern Medical Center, Dallas, ²Brigham and Women's Hospital, Boston, MA, ³Harvard Medical School, Wayland, MA, ⁴Department of Medicine, Perelman School of Medicine at the University of Pennsylvania, Philadelphia, PA, ⁵New York University School of Medicine, New York, NY, ⁶UT Southwestern Medical Center, Newton, MA
Background/Purpose: Psoriatic arthritis is a chronic systemic inflammatory disorder with significant impacts on health and life quality. Achieving good disease control in psoriatic arthritis (PsA)…
Abstract Number: 0632 • ACR Convergence 2024
Cutaneous Lupus Erythema and Scale Have Similar Six-month Trends Without Significant Impact from Race/ethnicity or Disease Subtype
Tyler Cepica¹, Lillian Xie², Daniella Faden², Caroline Stone³, Victoria Werth⁴ and Benjamin Chong⁵, ¹University of Texas Southwestern Medical School, Benbrook, TX, ²University of Pennsylvania, Philadelphia, PA, ³University of Pennsylvania, Phiiladelphia, PA, ⁴Hospital of the University of Pennsylvania, Philadelphia, PA, ⁵The University of Texas Southwestern Medical Center, Department of Dermatology, Dallas, TX
Background/Purpose: The Cutaneous Lupus Erythematosus Disease Area and Severity Index (CLASI) is a validated outcome measure designed to assess cutaneous lupus erythematosus (CLE) activity (CLASI-A)…
Abstract Number: 2655 • ACR Convergence 2024
Diagnostic Challenges of Dermatomyositis: A Retrospective Study of Its Dermatologic Mimics and Misdiagnoses
Aaron Bao¹, Eleni Tiniakou², Lisa Christopher-Stine³, Christopher Mecoli³, Jemima Albayda¹, Julie Paik³, William Kelly⁴ and Jun Kang⁵, ¹Johns Hopkins School of Medicine, Baltimore, MD, ²Johns Hopkins University, Lutherville Timonium, MD, ³Johns Hopkins University, Baltimore, MD, ⁴Johns Hopkins University, Hillsboro, NH, ⁵Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Dermatomyositis (DM) is often misdiagnosed due to its diverse clinical presentation. This study aimed to identify common dermatologic mimics of DM, characterize misdiagnosis rates…
Abstract Number: 0895 • ACR Convergence 2024
Procoagulant Extracellular Vesicles in Patients with Livedo Reticularis
Avital Baniel¹, Cristina Ricco², Rohan Dhiman³, Ahmed Eldaboush⁴, Caroline Stone⁴, Daniella Faden⁴, Luca Musante⁴, MIng-lin Liu⁴ and Victoria Werth⁵, ¹Perelman School of Medicine, UPENN, Philadelphia, PA, ²university of pennsylvania, Philadelphia, ³University of Pennsylvania, Newport Coast, CA, ⁴University of pennsylvania, Philadelphia, PA, ⁵University of Pennsylvania, Wynnewood, PA
Background/Purpose: Procoagulant activity is an important property of EVs. Connective tissue disease (CTD) patients with livedo reticularis (LR) are known for their procoagulant conditions. The…
Abstract Number: 0930 • ACR Convergence 2024
The Common Form of the Inflammatory Skin Disease Hidradenitis Suppurativa Is Associated with Low Nicastrin Expression in Dermal Fibroblasts
Kaitlin Williams, Beita Badiei, Hana Minsky and Luis Garza, Johns Hopkins University School of Medicine, Baltimore, MD
Background/Purpose: Hidradenitis suppurativa (HS) is a chronic inflammatory skin condition characterized by painful nodules and abscesses in intertriginous areas. Despite its increasing prevalence, the etiology…
Abstract Number: 0988 • ACR Convergence 2024
Antinuclear Antibody Positivity and Its Diagnostic Implications for Rheumatic Diseases in Dermatology Patients: A Comprehensive Single Center Analysis
Yunjung Choi¹, Myeung-Su Lee² and Wan-Hee Yoo³, ¹Jeonbuk National University Medical School, Deokjin-gu, Jeollabuk-do, Republic of Korea, ²Wonkwang University Hospital, Iksan, South Korea, ³CHONBUK NATIONAL UNIVERSITY HOSPITAL, JEONJU, Republic of Korea
Background/Purpose: Cutaneous manifestations are common in rheumatic diseases and can be early indicators. This study investigates the prevalence of rheumatic diseases diagnosed through ANA (Antinuclear…
Abstract Number: 1062 • ACR Convergence 2024
Assessing Musculoskeletal Symptom Burden in a Cohort of Patients with Hidradenitis Suppurativa Using the IDEOM MSK-Q
Gretchen Ball¹, Hassan Hamade², Sarah Romanelli², Zachary Levy², Lourdes Perez Chada³, Joseph Merola⁴ and Alice Gottlieb⁵, ¹Albert Einstein College of Medicine, Ridgefield, CT, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Brigham and Women’s Hospital, Harvard Medical School, Boston, MA, ⁴UT Southwestern Medical Center, Newton, MA, ⁵Icahn School of Medicine at Mount Sinai, Department of Dermatology, Seattle, WA
Background/Purpose: Hidradenitis suppurativa (HS) has been associated with inflammatory joint diseases such as psoriatic arthritis and ankylosing spondylitis. Despite this correlation, dermatologists do not routinely…
Abstract Number: 1131 • ACR Convergence 2024
Zasocitinib (TAK-279), a Selective Oral Tyrosine Kinase 2 Inhibitor, Reduces Body Surface Area Involvement in a Phase 2b Trial in Moderate-to-Severe Plaque Psoriasis
Vivian Laquer¹, Leon Kircik², Neil Sadick³, Jamie Weisman⁴, Yiwei Zhao⁵, Jessamyn Blau⁵, Wenwen Zhang⁶, Jonathan Uy⁵, Warren Winkelman⁶ and Melinda Gooderham⁷, ¹First OC Dermatology Research, Fountain Valley, CA, ²Icahn School of Medicine at Mount Sinai, New York, NY, ³Weill Cornell Medical College, New York, NY, ⁴Piedmont Atlanta, Atlanta, GA, ⁵Takeda Development Center Americas, Inc., Cambridge, MA, ⁶Takeda Development Center Americas, Inc., Cambridge, ⁷SKiN Centre for Dermatology and Probity Medical Research, Peterborough, ON, Canada
Background/Purpose: Zasocitinib (TAK-279) is a highly selective, allosteric, oral inhibitor of tyrosine kinase 2 (TYK2). TYK2 mediates signaling from cytokines involved in the pathogenesis of…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].